Digital Desk: Two of the candidates, which
contain inactivated or "killed" Omicron viruses and are similar to
Sinopharm's two vaccines in use in China, will be tested on adults who have
already received two or three vaccine doses, CNBG said in a statement.
The Sinopharm subsidiary said on
Saturday that two Covid-19 vaccine candidates developed by units of China
National Biotec Group (CNBG) to target the Omicron variant were approved for
clinical trials as boosters in Hong Kong.
Researchers
worldwide are racing to study newer injections against Omicron because
antibodies elicited by vaccines based on older strains show weaker activity
against this highly transmissible variant.
The two
candidates, both containing inactivated or "killed" Omicron virus and
similar to the two Sinopharm vaccines in use in China, will be tested in adults
who have already received two or three vaccine doses, CNBG said in a statement.
It did not
specify which vaccine products the trial participants would have received
before taking the experimental booster, or how many subjects would be
recruited.
According to a recent Chinese study, a fourth dose of Sinopharm's BBIBP-CorV vaccine did not significantly increase antibody levels against Omicron when administered six months after a third booster dose.
Researchers said that although the fourth dose restored antibody levels to about that of the third dose, new vaccines would be a better alternative to future boosters.
Also Read: India's first Omicron patient left Dubai after testing positive
|
|
